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LungAims: Prolactin is a major immunomodulator. The present study evaluated the effects of short-term
hyperprolactinemia induced by domperidone before ovalbumin antigenic challenge on the lung's allergic inﬂam-
matory response.
Mainmethods: To induce hyperprolactinemia, domperidonewas injected in rats at a dose of 5.1mg·kg−1 per day,
i.p., for 5 days from 10th to 14th day after OVA immunization. Total and differential leukocyte counts from bron-
choalveolar lavage (BAL), femoralmarrow lavage (FML), and bloodwere analyzed. The percentages ofmucus and
collagen productionwere evaluated. Levels of corticosterone and prolactin in serum, interleukin-4 (IL-4), IL-6, IL-
10, tumor necrosis factor α (TNF-α) in lung explants supernatants were measured and interferon gamma (IFN-
γ) in bronchiolar lavage cells suspensions (BAL) was measured.
Key ﬁndings: The rats that were subjected to short-term hyperprolactinemia exhibited a decrease in leukocyte
counts in bronchoalveolar lavage, cellularity decrease in femoral marrow lavage ﬂuid, a lower percentage of
mucus, and an increase in lung IL-4, IL-6, IL-10, TNF-α and IFN-γ expression.
Signiﬁcance:Hyperprolactinemia induced before antigenic challenge decreased allergic lung inﬂammation. These
data suggest that prolactin may play a role in the pathophysiology of asthma. The present study demonstrates a
prospective beneﬁcial side effect of domperidone for asthmatic patients.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Gastro-esophageal reﬂux disease (GERD) and asthma are frequently
associated with each other. It is estimated that GERD is present in 60–
80% of asthmatic adults and 50–60% of asthmatic children. There is con-
siderable debate regarding the nature of this association, but GERD ap-
pears to be an important trigger for asthma and a risk factor for
worsening symptoms, asthma-related hospitalization, and the require-
ment for oral steroids. Some studies have shown that anti-reﬂux thera-
py with domperidone improves asthma control in patients with
symptomatic GERD [40]. Few studies of dopamine antagonist treatment
for asthma have been conducted in humans, but case reports have de-
scribed the use of domperidone in patients with GERD associated with
asthma [21,42]. Several explanations have beenmade for the apparentlyhe subject matter of this article.
e Paiva, 87 CidadeUniversitária,paradoxical ﬁndings that medical antireﬂux therapy improves asthma
symptoms, but not lung function [21]. However, improvements in
lung function have been reported, attributable to the inhibition of bron-
chial hyperresponsiveness [22]. Thus, considering the possible thera-
peutic use of domperidone, the mechanisms by which it affects the
lungs' allergic inﬂammatory response and moderates immune and in-
ﬂammatory processes in asthma need to be explained.
Asthma is an inﬂammatory disease caused by repeated immediate-
phase hypersensitivity and late-phase allergic reactions in the lungs,
leading to the clinicopathologic triad of intermittent and reversible air-
way obstruction, chronic bronchial inﬂammation with eosinophils,
bronchial smooth muscle cell hypertrophy, and hyperreactivity to
bronchoconstrictors. The pathophysiologic sequence of atopic asthma
is likely initiated by mast cell activation in response to allergen binding
to immunoglobulin E (IgE) and Th2 cells that react to allergens [1] and
produce inﬂammation. The inﬂammation is controlled by cytokines of
the Th2 cluster. These cytokines include interleukin 4 (IL-4) and IL-13
(which regulates IgE production), IL-5 (which is heavily implicated in
eosinophilia), and the counterregulatory cytokines IL-10 and
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activate other cells that contribute to the remodeling of airways [40]. In-
creasedmucus secretion results from the action of cytokines, mainly IL-
13, on bronchial epithelial cells [1].
Prolactin (PRL) is a peptide hormone that is secreted from the ante-
rior pituitary gland under tonic inhibition by the hypothalamus via do-
pamine [5,36]. Prolactin is involved in more than 300 different
functions, [6] and its functionality depends on the type of cells that ex-
press the PRL receptor. Based on its molecular and functional character-
istics, it is a cytokine [36] and participates in innate and adaptive
immune responses [23]. During an immune response, PRL promotes
the proliferation and differentiation of T cells and inﬂuences the expres-
sion of CD69 and CD154 in CD4T cells [6]. Prolactin possesses signiﬁcant
immunomodulatory properties because regulatory T cells constitutively
express the PRL receptor [13]. This study was designed to test if
hyperprolactinemia induced before antigenic challenge interferes with
allergic lung inﬂammation.
2. Materials and methods
2.1. Animals
Male Wistar rats were obtained from the Department of Pathology
Animal House, School of Veterinary Medicine, University of São Paulo.
The animals were housed in rooms with ventilation at a constant tem-
perature of 22–23 °C under a ﬁxed 12 h/12 h light/dark cycle (lights
on at 6:00 AM)with free access to food andwater. All of the procedures
were performed in strict accordance to the guidelines of the Colegio
Brasileiro de Experimentação Animal and National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
2.2. Allergic lung inﬂammation model in rats
The rats were sensitized with 10 μg ovalbumin (OVA; Egg Albumin
Grade II, Sigma-Aldrich, St. Louis, MO, USA) [14,25] and 10 mg alumi-
num hydroxide (EMS Pharmaceuticals, Brazil) dissolved in phosphate-
buffered saline (PBS) and administered subcutaneously on day 0 at a
dose of 0.1 mg·kg−1. One week later (day 7), rats were boosted subcu-
taneously with the same treatment. For the challenge with OVA aerosol
(1% in PBS), animals were individually placed in an inhalation chamber
connected to an ultrasonic nebulizer for 15 min per day for 3 consecu-
tive days (days 15, 16, and 17) according to previous studies [19,26].
2.3. Experimental hyperprolactinemia
Hyperprolactinemia was induced by the dopamine receptor blocker
domperidone (Johnson & Johnson, Brazil). Although domperidone does
not cross the blood–brain barrier,[28] it acts on hypophysis and in-
creases PRL secretion [12,20,34]. Domperidone was administered at a
dose of 1.7 mg/kg (i.p.) three times per day (6:30 AM, 2:00 PM, and
9:00 PM) for 5 consecutive days [34,35] from 10th to 14th day afterFig. 1. ExperimeOVA immunization. This treatment protocol has effectively produced
stable hyperprolactinemia for more than 30 days [2].2.4. Experimental outline
Male rats, 60–90 days of age, were randomly divided into four
groups: naive group with no treatment and no lung allergy (N), control
group (C), vehicle group (V), and domperidone group with induced
lung allergy and respective treatments (D).
On day 0, the C, V, andD groupswere injectedwithOVA and boosted
on day 7. Between days 10 and 14, the D group was treated with
domperidone as described above, whereas the V group was adminis-
tered 0.9% NaCl. On days 15, 16, and 17, the C, V, and D groups received
OVA in aerosol form to induce lung allergy. The experimental outline is
depicted in Fig. 1.2.5. Sample collection
On day 18, 24 h after the last OVA challenge, the animals were anes-
thetized with 5 mg·kg−1 of 2% xylazine hydrochloride (Konig; i.p.) and
30 mg·kg−1 of 5% ketamine (Ketalar; Konig; i.p.). The peritoneal cavity
was opened, and blood was collected through the abdominal aorta in
plastic syringes that contained 50 μl of 8% ethylenediamine tetraacetic
acid (EDTA). Blood was set aside until clot formation and then immedi-
ately centrifuged for serum collection, which was stored at−80 °C. All
blood collections were performed with the same schedule to avoid cir-
cadian rhythms effects. Subsequently, the lungswerewashed four times
with 5.0 ml heparinized PBS (20 ml) through a polyethylene cannula
(1 mm inner diameter) inserted by tracheotomy. Bronchoalveolar la-
vage (BAL) was performed according to previous data [18]. Recovered
BAL ﬂuid was centrifuged at 170 ×g for 10min at 4 °C. The supernatant
was discarded, and the resulting pellet was resuspended in PBS (1 ml).
Rat femurs were removed, and a needle connected to a plastic syringe
containing 5 ml PBS was inserted into each femoral marrow to allow
cell collection by ﬂushing. The femoral marrow lavage (FML) ﬂuid was
centrifuged at 170 ×g for 10 min, and the cell pellet was resuspended,
processed, and analyzed for total leukocyte counts [19,26] The adrenal
glands were then removed and weighed. The relationship between
the wet weight of the two adrenal glands (in milligrams) and body
weight (in grams) was also analyzed, calculated, and compared
among groups. Lung samples were also collected for explant culture
and ﬁxation for histochemistry.2.6. Total and differential whole-blood counts
Samples were diluted 1:20 in Turk liquid (3% acetic acid) and count-
ed in a Neubauer chamber. Blood smears were stained with May–
Grünwald–Giemsa, and differential leukocytes were counted by light
microscopy [19,26].ntal outline.
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The total number of bone marrow cells was quantiﬁed in FML ﬂuid
using Turk solution in a Neubauer chamber.2.8. Bronchoalveolar lavage leukocyte counts
Bronchoalveolar lavage cell suspensionswere diluted 1:20with Turk
solution, and total leukocyteswere counted in aNeubauer chamber. Dif-
ferential cell counts were performed using cytocentrifuge preparations
(Cytospin, Fanem, Brazil) and stained with May-Grünwald–Giemsa so-
lution [19,26].2.9. Prolactin and corticosterone measurements
Serum PRL levels were determined by radioimmunoassay [33]. The
PRL assay has 0.19 ng/ml sensitivity and inter-assay and intra-assay co-
efﬁcients of variation of 11.5% and 4.0%, respectively [9,10]. Serum cor-
ticosterone levels were determined using a commercial enzyme-linked
immunoassay (ELISA) kit (Arbor Assays, #K014) according to the
manufacturer's instructions, with 1:300 serum dilution.2.10. Lung explant culture and medium cytokine analysis
Cytokine production (IL-4, IL-6, IL-10, and TNF-α) was determined
in supernatant samples of lung explants maintained in culture of the
naïve, control, vehicle e domperidone groups and stimulated with
OVA. Lung samples of the four groups were cut randomly into four
small pieces, then distributed into 24-well plates that were ﬁlled with
1 ml of Dulbecco's modiﬁed Eagle medium (DMEM) that contained
0.5% penicillin/streptomycin (10,000 IU, 10 mg·ml−1), and with 1 mg/
ml OVA treatment, and incubated for 24 h at 37 °C with 5% CO2. The re-
sults are expressed as picograms (pg) of cytokine produced per milli-
gram dry weight of lung tissue. Cytokines were quantiﬁed using
commercial ELISA kits (BD OptEIA rat cytokine ELISA kits, BD Biosci-
ences) [19].2.11. Cytokine production in BAL
The concentrations of cytokines and chemokines in BAL specimens
were measured with an enzyme-linked immunosorbent assay (ELISA;
R&D Systems, USA). The range of curve was: 39.10–2500 pg/ml.Fig. 2.Domperidone increases prolactin serum levels. Effects of domperidone before oval-
bumin (OVA) inhalation on serum prolactin levels (A), and serum corticosterone levels
(B). N, naive group; C, control group; V, vehicle group; D, domperidone group. Different
letters above the columns indicate signiﬁcant differences. The data are expressed asmedi-
an ± SE, interquartile intervals, and maximum and minimum values. Prolactin: p b 0.01
(ANOVA and Newman–Keuls multiple-comparison test). Corticosterone: p b 0.05
(Kruskal–Wallis test followed by Mann–Whitney test). Different letters above the col-
umns indicate signiﬁcant differences.2.12. Quantiﬁcation of lung mucus and collagen
Lung samples were ﬁxed in 10% formalin and processed by routine
histological methods. Sections (3–4 mm thickness) were stained with
hematoxylin and eosin (HE) and periodic acid Schiff (PAS) to detect
mucus production and picrosirius to observe the presence of collagen ﬁ-
bers. An area was estimated between the inner and muscularis edge
mucosa and ﬁve bronchioles in each animal using were imaged at
100× magniﬁcations using a Nikon Eclipse 80i microscope, camera in-
ﬁnity and the software ImagePro Plus 5.0 software (Media Cybernetics,
Silver Spring, MD, USA). The color threshold for picrosirius and periodic
acid Schiff (PAS) were determined and the analyses were performed as
follows: using the previously determined color threshold for mucus
(PAS positive), the amount of PAS area was determined and results
were expressed as the % of PAS area compared to the total epithelium;
using the previously determined color threshold for picrosirius and
the picrosirius-positive area was quantiﬁed. These results were
expressed as the % of collagen (picrosirius positive) area compared to
the total measured area [43].2.13. Statistical analysis
Data distribution was veriﬁed using Kolmogorov–Smirnov test.
Parametric data were analyzed using ANOVA followed by Student–
Newman–Keuls post hoc test. Kruskal–Wallis test was applied for non-
parametric data, and comparisons were made using Mann's U test. All
of the statistical analyses were performed using GraphPad Instat 5.01
software.3. Results
3.1. Domperidone increases prolactin serum levels
The experimental outline is depicted in Fig. 1. Serum PRL levels are
presented in Fig. 2A. Prolactin levels in domperidone-treated animals
were approximately nine-times higher than in animals from the other
groups (p b 0.01).
Animals treated with domperidone exhibited lower serum cortico-
sterone levels compared with the C group (p=0.01), but no signiﬁcant
difference was found between the V and D groups (p= 0.96; Fig. 2B).
The C group had higher corticosterone levels than the V group (p =
0.01, U = 4.00) and D group (p b 0.01).
69J.E. Ochoa-Amaya et al. / Life Sciences 142 (2015) 66–75The absolute weight of the adrenal gland and ratio between the
weight of the adrenal gland and bodyweight (mg·g−1) were not signif-
icantly different between groups (data not shown).
3.2. Domperidone inhibits OVA/induced increase in BAL inﬂammatory cells
Fig. 3A shows that the C group exhibited a greater number of cells
(p b 0.05) in BAL ﬂuid compared with the N and D groups, but no differ-
ence was found between the C and V groups. The total cell number in
BAL ﬂuid was signiﬁcantly higher in the V group than in the N group,
but no signiﬁcant difference was found between the N and D groups
(p N 0.05). Differential cell analyses in BAL ﬂuid revealed thatFig. 3. Domperidone inhibits OVA-induced increase in BAL inﬂammatory cells. Effects of domp
ferential leukocyte counts in BAL ﬂuid (B), the total number of cells in whole blood (C), differen
naive group; C, control group; V, vehicle group; D, domperidone group.Different letters above th
p b 0.005. Differential BAL: p b 0.05. Total whole blood: p N 0.05. Differential whole blood: p b 0.macrophage counts in the C group were higher than in the N group
(p b 0.05; Fig. 3B). With regard to lymphocytes, the highest lung migra-
tion was observed in the C group (p b 0.05) compared with the N group
(p=0.02), but the C groupwas not signiﬁcantly different from the D or
V group. A signiﬁcant difference in lymphocyte counts was found be-
tween the N and V groups (p= 0.01), but no difference was found be-
tween the N and D groups. Eosinophil lung migration was the highest
in the C group, followed by signiﬁcantly lower counts in the V and D
groups, with signiﬁcant differences between groups (p b 0.05).
No signiﬁcant differences in total leukocyte blood cellularity were
found between groups (Fig. 3C). The C group had different circulating
cell counts from the other three groups, but this did not reach statisticaleridone treatment before OVA inhalation on the total number of cells in BAL ﬂuid (A), dif-
tial leukocyte counts in whole blood (D), the total number of cells in bonemarrow (E). N,
e columns indicate signiﬁcant differences. The data are expressed asmean±SE. Total BAL:
05. Total bonemarrow: p b 0.005 (ANOVA and Newman–Keuls multiple-comparison test).
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number of neutrophils was signiﬁcantly different for the C group (p b
0.05), which had a higher number of neutrophils compared with the
N group (p b 0.01); and V group (p b 0.01). Blood eosinophil counts
were higher in C group when compared numerically between D
group, but this did not reach statistical signiﬁcance (p N 0.05). No signif-
icant differences in blood lymphocyte andmonocyte countswere found
between groups.
FML cellularity was not signiﬁcantly different between the D group
and C and V groups (Fig. 3E). Compared with the N group, the D, C,
and V groups presented signiﬁcantly lower FML cellularity (p b 0.05).
Eosinophils are central effector cells in allergic lung inﬂammation
and are responsible for airway inﬂammation.We evaluated the correla-
tion between plasma PRL levels and eosinophil chemotaxis and migra-
tion to the lung in allergic animals. Allergic animals that had high PRL
levels due to domperidone treatment presented lower eosinophil mi-
gration. A correlation coefﬁcient of r =−0.18, conﬁdence interval of
−0.73 to 0.51, and p = 0.62 were considered an inverse association
(Fig. 4).
The percentage of collagen among the different treatment groups (C,
V, and D) was not signiﬁcantly different (p N 0.05), but the C, V, and D
groups presented higher collagen deposition than the N group
(p b 0.05; Fig. 5A, B).
3.3. Domperidone inhibits OVA-induced increase in peribronchiolar mucus
deposition
Mucus production in the D groupwas signiﬁcantly lower than in the
V group (p b 0.01; Fig. 6A, B). Mucus production was higher in the D
group than in the N group (p b 0.01) but not signiﬁcantly different be-
tween the D and C groups. Mucus production was not signiﬁcantly dif-
ferent between the C and V groups, whereas the C group had higher
mucus production than the N group (p b 0.01).
3.4. Domperidone increases IL-6 and IL-10 levels
To investigate changes in cell migration to the lung, we evaluated
the effects of PRL on the production of IL-4, IL-6, IL-10, TNF-α in super-
natant samples of lung explants in culture, and IFNg in bronchiolar la-
vage cells suspensions (BAL), in allergic rats (Fig. 7). The
concentrations of IL-4 (p= 0.03), IL-6 (p b 0.01), and IL-10 (p b 0.01)
in the supernatants in domperidone-treated rat lung explants were sig-
niﬁcantly higher than in the supernatants of lung explants obtained
from the N, V, and C groups that were challenged again with OVA
in vitro. Signiﬁcant differences in TNF-α were found between the DFig. 4. Correlation between prolactin levels and eosinophil chemotaxis to the lung in sen-
sitized rats challenged with OVA in the domperidone group. Data points are expressed as
mean values.and V groups (p=0.01). Group D exhibited higher IFN-g concentration
in the BAL when compared to vehicle and naïve groups (p b 0.01).
4. Discussion
The present study evaluated the effects of short-term
hyperprolactinemia induced by domperidone before ovalbumin anti-
genic challenge on the lung's allergic inﬂammatory response.
Hyperprolactinemia induced before antigenic challenge decreased al-
lergic lung inﬂammation. These data suggest that prolactin may play a
role in the pathophysiology of asthma.
Domperidone blocks dopamine D2 receptors, particularly within the
tuberoinfundibular dopaminergic system, and induces
hyperprolactinemia [2,17,20,32,34]. The present results conﬁrm this ef-
fect of domperidone and are consistent with previous ﬁndings from our
laboratory [11,32,34,35].
Much of what we know about the pathogenesis and pathophysiolo-
gy of asthma has been derived from human and animal studies of aller-
gic asthma, but some caution is needed in extrapolating the data from
these models to better understand what occurs in nonatopic asthma.
Asthma does not occur in rodents or other nonhuman animals, and par-
ticular care is needed when applying data from animal models of asth-
ma, most of which would be more accurately described as models of
airway inﬂammation caused by allergic sensitization [40]. Nevertheless,
this asthma model was successfully applied in the present study.
The results of the BAL analysis in the asthmatic groups (C, V, and
D) demonstrated that the animals had higher cell migration to the
lungs as a response to the allergic inﬂammatory process induced by
OVA compared with the N group, which represented baseline lung
cellularity.
Differential counts in BAL ﬂuid in the V group were signiﬁcantly dif-
ferent from the C group, suggesting that vehicle treatment was not
completely innocuous. The C group exhibited a greater number of cells
in BAL ﬂuid, possibly because of an increase in the migration of bone
marrow cells in response to allergic pulmonary inﬂammation induced
by OVA. The D group had a decreased population of eosinophils com-
pared with the C and V groups. The D group had higher PRL levels and
lower eosinophil migration. Therefore, this might suggest a causal rela-
tionship, in which hyperprolactinemia reduces migrating eosinophils.
When we analyzed the total cell number in bone marrow, the
hyperprolactinemic D group exhibited a smaller number of total cells
compared with the N group, which represented baseline bone marrow
cellularity. The reduction of bonemarrow cells in the D groupwas asso-
ciated with the lowest number of cells in BAL ﬂuid and blood, which
may have been caused by hyperprolactinemia. Thus, domperidone
treatment before the challenge had anti-inﬂammatory effects in the
lungs in allergic rats. These effects may be attributable to the effect of
short-term domperidone-induced hyperprolactinemia on
lymphopoiesis [48]. These authors studied the ability of recombinant
human prolactin (rhPRL) to stimulate the growth ofmurine hematopoi-
etic progenitor cells in vitro. In this study, the authors conﬁrmed that
the observations made in mouse cells can be extended to humans. Pro-
lactin failed to increase the granulocyte-macrophage progenitor (CFU-
GM) and growth of committed erythroid progenitors (BFU-E) when
PRL was added to the cultures at various concentrations (1–
1000 ng/ml) or to unfractionated bone marrow [49]. There is a correla-
tion between PRL levels and the number of CD4+ T lymphocytes and B
lymphocytes, but prolactin is not essential for lymphopoiesis [36,48].
Prolactin might act directly on its own receptors on progenitor cells in
bonemarrow. The interaction between PRLwith PRL receptors activates
the JAK family of kinases. This pathway phosphorylates STAT5 latent
proteins, conferring DNA binding capacity to STAT and resulting in the
transcriptional activation of certain genes, such as STAT1, STAT3, and
STAT5b. This pathway also activates the transcription of key genes in
the development of the Th1 response, such as T-bet factor. The tran-
scription of this gene is activated even by low concentrations of PRL
Fig. 5. Lack of evidence of domperidone effect on OVA-induced increase peribronchiolar collagen deposition. Representative images of collagen stainingwith picrosirius in each treatment
group (A, naïve; B, control; C, vehicle; D, domperidone). The arrows indicate positive picrosirius collagen staining. Effects of domperidone treatment before OVA inhalation on the percent-
age of collagen in the inﬂammatory response of the lungs (E). N, naive group; C, control group; V, vehicle group; D, domperidone group. Different letters above the columns indicate sig-
niﬁcant differences. The data are expressed as mean ± SE. p b 0.05 (ANOVA and Newman–Keuls multiple-comparison test).
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[6,23]. Low doses of PRL elicit a pro-inﬂammatory response and pro-
mote antibody production, whereas high doses suppress these re-
sponses. Growth hormone, insulin-like growth factor 1, and PRL could
promote growth effects on immune response cellular function through
cytokine release [48].
IL-4 has a central function in the promotion of eosinophilic inﬂam-
matory reaction in allergic diseases, through the activation of IgE
isotype [37]. The D group presented higher IL-4 concentrations than
only the N group and higher TNF-α expression than the V group (p b
0.05). Prolactin promotes pro-inﬂammatory immune responses via
NFκB and interferon regulatory factor (IRF-1). These cited factors are
known to induce TNF-α increase, considered essential inﬂammation
mediator [35], which can affect pathophysiological processes during
hyperprolactinemic conditions [8]. TNF-α contributes to a dysregulated
inﬂammatory response in the airways of asthmatics, in part by inducing
the epithelial expression of pro-inﬂammatory cytokines and adhesion
molecules [24], which was observed in the hyperprolactinemic groupwith increases in IL-6, IL-10 and IFN-g secreting cells. IFN-g production
in BAL is higher on the hyperprolactinemic group.
Prolactin induces the transcription of interferon regulatory factor
(IRF-1) that is a multifunctional transcription factor, and an important
regulatory factor of the differentiation and maturation of the lympho-
cytes T and B [30]. In T lymphocytes, IRF-1 is critical for the development
and Th1 response, as well as their proliferation and apoptosis. In Nb2 T
cells, IRF-1 is induced by prolactin stimulation as part of the initial G1
activation [50]. IRF-1 regulates the expression of important genes that
mediate the immune response, host defense, cell cycle progression, tu-
moral suppression and apoptosis [47]. Consistently, prolactin promotes
the Th1 immunology response, which is associated with activation of
the cellular response, with macrophages activation, and with IFNg syn-
theses in the NK cells and T lymphocytes [30].
TNF-α stimulates ACTH, growth hormone, thyroid-stimulating hor-
mone, and PRL secretion in rat pituitary cells in vitro. In contrast, TNF-
α was found to inhibit the release of ACTH and other hormones in re-
sponse to hypothalamic factors by acting directly on pituitary cells [39].
Fig. 6.Domperidone inhibits OVA-induced increase in peribronchiolar mucus deposition. Representative images ofmucus stainingwith PAS in each treatment group. The arrows indicate
positive PAS mucus staining (A, naïve; B, control; C, vehicle; D, domperidone). Effects of domperidone treatment before OVA inhalation on the percentage of mucus in the inﬂammatory
response of the lungs (E). N, naive group; C, control group; V, vehicle group; D, domperidone group. Different letters above the columns indicate signiﬁcant differences. The data are
expressed as mean ± SE. p b 0.05 (ANOVA and Newman–Keuls multiple-comparison test).
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volved in the inﬂammatory response [4]. Increases in IL-6 levels stimu-
late the secretion of ACTH, and IL-6 plays a role in activating the
hypothalamic–pituitary–adrenal axis [39]. The concentrations of IL-6
and IL-10 in rat lung explants in the D group in the present study
were higher than in the N, V, and C groups challenged with OVA. IL-6
levels were signiﬁcantly different between the hyperprolactinemic
group treated with domperidone and the other three groups (N, V,
and C). T lymphocytes activation mediated by prolactin pathways, pro-
lactin receptors (PRL-R) and JAK2/Stat5, lead to the production and re-
lease of a range of cytokines including IL-1, IL-4, IL-5, IL-6, IL-10 and
IFN-g, which stimulated activated B cells to proliferate and differentiate.
These ﬁndings support the notion that prolactin favors tolerance by
modulating the biological activity of several cell types and tissues, as
well as many aspects of the immune response [47]. Prolactin concentra-
tion is an important modulatory factor of the inﬂammatory response[30,38]. Prolactin has an important physiological role in maintaining of
survival and function of the immune system in stress conditions,where-
in both prolactin and glucocorticoids are elevated but with opposed
functions [30].
However, corticosterone levels in the hyperprolactinemic group
were low and different from the N and C groups. These results are con-
sistent with the physiological antagonism of ACTH and corticosteroids
by PRL in stress situations [34]. As such the administration of prolactin
after the hemorrhage improves the function of the macrophages and
splenocytes, and reduces both levels plasma corticosterone andmortal-
ity [31]. Prolactin reverses the effects of corticosteroids and increases
the Th1 type of cellular responses [13]. Thus, Th1 responses in the asth-
ma model might be anti-inﬂammatory. This is consistent with the ob-
servations in this study. These results are consistent with the ﬁndings
of other authors who reported that PRL promotes the secretion of Th1
cytokines in vivo and in vitro [6,13,30]. In mice, high levels of PRL
Fig. 7. Domperidone increases IL-6 and IL-10 levels. Effects of domperidone treatment before OVA inhalation on the expression of inﬂammatory cytokines in allergic rats. IL-4, IL-6, IL-10,
and TNFαwere measured in supernatants of lung explants and IFNg was measured in BAL. (A) IL-4. (B) IL-6. (C) IL-10. (D) TNF-α. (E) IFNg. N, naive group; C, control group; V, vehicle
group; D, domperidone group. Different letters above the columns indicate signiﬁcant differences. The data are expressed as mean ± SE. IL-4: p b 0.05 (Kruskal–Wallis test, followed
by Mann–Whitney test). IL-6: p b 0.01 (ANOVA and Newman–Keuls multiple-comparison test). IL-10: p b 0.0001 (ANOVA and Newman–Keuls multiple-comparison test). TNF-α:
p b 0.05 (Kruskal-Wallis test, followed by Mann–Whitney test). IFNg: p b 0.0001 (Kruskal–Wallis test, followed by Dunn's Multiple Comparison post test).
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[13] Th1 cells secrete IL-2 and IFNg,whose function is to inhibit bronchi-
al asthma [3].
Prolactin is also able to modulate the response of Th1 cells to exoge-
nous IL-2 and the response of B and T cells to competence factors
(e.g., mitogens). This modulatory action can be either positive or nega-
tive, depending on the concentration of the hormone. However, the
stimulatory effect of PRL was decreased at high concentrations(200 ng/ml), and comparable amounts of IL-2 are also known to effec-
tively increase NK cell proliferation [27]. Prolactin is a versatilemolecule
and this depends on both its structural polymorphism and thewide dis-
tribution of its membrane receptors [30].
IL-10 prevents eosinophil deposition and activation, induced by the
allergen in animal asthma models. It also regulates the cellular immune
response [37]. The D group exhibited an increase in the levels of IL-10, a
cytokine that is produced by Th2 cells, B cells, and macrophages. IL-10
74 J.E. Ochoa-Amaya et al. / Life Sciences 142 (2015) 66–75acts on antigen-expressing cells by inhibiting their function [4].
Hyperprolactinemia in this group activated a control system by IL-10,
thereby limiting pro-inﬂammatory reactivity [34]. When IL-10 is in-
creased in allergic diseases, it suppresses the activity of mast cells and
neutrophils. IL-10 has also been associated with the reduced synthesis
of IgE in allergic responses that involve mast cells [19]. High prolactin
doses (1000 ng/ml) in murine macrophages induced increase of IL-10
synthesis [16,38] with signiﬁcant suppression of cytokine production
in the same cell line, correlated to pSTAT3 expression [38].
In addition, high levels of pro-inﬂammatory Th2 cytokines as IL-5,
[51] IL6 [52] and a low proﬁle of Th1 cytokines as IFN-g [37] and anti-
inﬂammatory cytokine IL10 [45] have been observed in asthmatic pa-
tients. It needs to be recognized that activated vitamin D (calcitriol)
modulates the immune response through inhibition or enhancement
on multiple levels of cell function, such as production of both pro- and
anti-inﬂammatory cytokines, and inhibition of B cell differentiation,
proliferation, and antibody secretion. Activated vitamin D enhances
the development of interleukin-IL-10- and reduces the number of IL-
6- and IL-17-secreting cells [15].
Vitamin D seems to act similarly to prolactin. Both vitamin D and
prolactin increase IL-10. Thus part of the effects reported in this article
may be due to vitamin D actions in addition to those of prolactin.
Domperidone has limitations as a model for hypeprolactinemia. Since
this drug blocks peripheral dopamine receptors and some immune
cells have dopamine receptors, this very action may have inﬂuenced
the response of those immune cells [44,46]. In vitro studies have ad-
dressed this issue [9–11]. Yet, future studies will address the question
whether prolactin actions described here occur using one or more of
the different prolactin signaling pathways. Neuron-speciﬁc STAT5
knockout mouse may be a useful tool to address this issue [7].
In the present study, the histochemical results showed purple colla-
gen staining, thus allowing its quantiﬁcation. Several regulatory cyto-
kines that are produced by T cells and eosinophils have proﬁbrotic
effects, such as TGF-β, IL-10, and IL-17. The concentrations of these cy-
tokines may increase in the airways of allergic humans. They promote
ﬁbrosis by decreasing the activity of T and B cells [40]. All of the treat-
ment groups (C, V, and D) exhibited higher collagen staining compared
with naive animals. TNF-αmay also play a more integrated role in air-
way remodeling and the repair response that occurs as a result of the in-
ﬂammatory response and is associated with airway epithelial injury
through the modulation of epidermal growth factor receptors [41].
Airway epithelial cells also secrete mucus when stimulated with
TNF-α [41]. The D group had higher levels of TNF-α than the V group.
Therefore, the D group exhibited the highest levels of mucus compared
with the N group. These results are consistentwith those described pre-
viously [29]. These authors reported that theproduction of TNF-α (mea-
sured by the MTT assay/cytotoxicity assay) by neutrophils was
markedly increased in mice treated with PRL and in mice that received
ectopic pituitary grafts compared with controls. Nonetheless, the D
group exhibited a decrease in mucus production compared with the V
group.
5. Conclusion
In summary, the present results suggest that an anti-asthmatic effect
resulted from hyperprolactinemia induced after ovalbumin treatment.
Hyperprolactinemia induced before antigenic challenge decreased al-
lergic lung inﬂammation. The role played by endogenous PRL as a rele-
vant immunomodulator of asthma appears likely. This study shows a
prospective beneﬁcial side effect of domperidone for asthmatic patients.
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